Amisulpride versus risperidone treatment for behavioral and psychological symptoms in patients with dementia of the Alzheimer type: a randomized, open, prospective study.

Lim, Hyun-Kook; Pae, Chi-Un; Lee, Chul; Lee, Chang-Uk
Neuropsychobiology
2006NA ; 54 ( 4 ) :247-51.
ÀúÀÚ »ó¼¼Á¤º¸
Lim, Hyun-Kook -
Pae, Chi-Un -
Lee, Chul -
Lee, Chang-Uk -
ABSTRACT
The aim of this study was to evaluate the effectiveness and tolerability of both amisulpride and risperidone for treating the behavioral and psychological symptoms of dementia in patients with dementia of the Alzheimer type (DAT). Twenty-eight patients with DAT were randomly assigned to treatment with either amisulpride or risperidone for 8 weeks. The effectiveness of the treatments was assessed with the Neuropsychiatric Inventory (NPI) and the Clinical Global Impression-Severity of Illness (CGI-S) scale. The Simpson-Angus Rating Scale, the Barnes Akathisia Rating Scale and the Abnormal Involuntary Movement Scale were used for the assessment of side effects. The NPI and CGI-S scores were significantly decreased over time in both treatment groups without any significant group difference and time by treatment group interaction effect (F=71.85, p<0.0001). There were no serious adverse events in both groups. This study showed that either amisulpride or risperidone would be effective and tolerable for treating patients with DAT. Adequately powered studies with a head-to-head comparison design will be mandatory to draw any definite conclusion. CI - (c) 2006 S. Karger AG, Basel.
Behavioral and psychological symptoms of dementia ¡¤ Amisulpride ¡¤ Risperidone ¡¤ Dementia of the Alzheimer type
MESH
Aged, Aged, 80 and over, Alzheimer Disease/complications/drug therapy, Antipsychotic Agents/*therapeutic use, Behavioral Symptoms/*drug therapy/etiology, Female, Humans, Male, Prospective Studies, Psychiatric Status Rating Scales, Psychotic Disorders/*drug therapy/etiology, Risperidone/*therapeutic use, Severity of Illness Index, Sulpiride/*analogs & derivatives/therapeutic use, Time Factors
¸µÅ©

ÁÖÁ¦ÄÚµå
ÁÖÁ¦¸í(Target field)
¿¬±¸´ë»ó(Population)
¿¬±¸Âü¿©(Sample size)
´ë»ó¼ºº°(Gender)
Áúº´Æ¯¼º(Condition Category)
¿¬±¸È¯°æ(Setting)
¿¬±¸¼³°è(Study Design)
¿¬±¸±â°£(Period)
ÁßÀç¹æ¹ý(Intervention Type)
ÁßÀç¸íĪ(Intervention Name)
Å°¿öµå(Keyword)
À¯È¿¼º°á°ú(Recomendation)
This study showed that either amisulpride or risperidone would be effective and tolerable for treating patients with DAT; The Neuropsychiatric Inventory (NPI) and the Clinical Global Impression-Severity of Illness (CGI-S) scores were significantly decreased over time in both treatment groups without any significant group difference and time by treatment group interaction effect (F = 71.85, p < 0.0001).
¿¬±¸ºñÁö¿ø(Fund Source)
±Ù°Å¼öÁØÆò°¡(Evidence Hierarchy)
ÃâÆdz⵵(Year)
Âü¿©ÀúÀÚ¼ö(Authors)
´ëÇ¥ÀúÀÚ
DOI
https://doi.org/10.1159/000100779
KCDÄÚµå
ICD 03
°Ç°­º¸ÇèÄÚµå